Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) were down 0% during mid-day trading on Thursday . The stock traded as low as $18.24 and last traded at $18.64. Approximately 48,777,184 shares changed hands during mid-day trading, an increase of 140% from the average daily volume of 20,284,979 shares. The stock had previously closed at $18.64.
Several analysts have issued reports on TEVA shares. Goldman Sachs Group upped their target price on Teva Pharmaceutical Industries from $20.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, January 11th. Credit Suisse Group restated an “underperform” rating and issued a $8.00 target price (down from $14.00) on shares of Teva Pharmaceutical Industries in a report on Monday, November 6th. Morgan Stanley upgraded Teva Pharmaceutical Industries from an “underweight” rating to an “equal weight” rating and set a $18.00 target price for the company in a report on Friday, December 15th. Royal Bank of Canada set a $11.00 target price on Teva Pharmaceutical Industries and gave the company a “sell” rating in a report on Wednesday, November 29th. Finally, Cantor Fitzgerald set a $10.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Thursday, December 14th. Nine research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have assigned a buy rating to the company’s stock. Teva Pharmaceutical Industries has a consensus rating of “Hold” and a consensus target price of $21.54.
The stock has a market capitalization of $18,760.00, a price-to-earnings ratio of -3.18, a price-to-earnings-growth ratio of 1.48 and a beta of 0.59. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66.
A number of institutional investors have recently made changes to their positions in the stock. Northern Cross LLC boosted its holdings in Teva Pharmaceutical Industries by 14.0% during the 2nd quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock valued at $591,169,000 after acquiring an additional 2,184,172 shares during the period. Schroder Investment Management Group boosted its holdings in Teva Pharmaceutical Industries by 22.7% during the 3rd quarter. Schroder Investment Management Group now owns 6,194,083 shares of the company’s stock valued at $106,290,000 after acquiring an additional 1,147,683 shares during the period. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in Teva Pharmaceutical Industries by 4.5% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 6,035,644 shares of the company’s stock valued at $106,271,000 after acquiring an additional 259,891 shares during the period. State Street Corp boosted its holdings in Teva Pharmaceutical Industries by 5.1% during the 2nd quarter. State Street Corp now owns 4,763,692 shares of the company’s stock valued at $158,254,000 after acquiring an additional 232,924 shares during the period. Finally, Macquarie Group Ltd. raised its position in Teva Pharmaceutical Industries by 350.3% in the 3rd quarter. Macquarie Group Ltd. now owns 4,408,331 shares of the company’s stock valued at $77,587,000 after purchasing an additional 3,429,448 shares in the last quarter. Institutional investors own 51.99% of the company’s stock.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.